Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials

被引：0
|
作者：
Helene O. Larsen
Jakob Grauslund
Anna S. Vergmann
机构：
[1] Odense University Hospital,Research Unit of Ophthalmology, Department of Ophthalmology
[2] University of Southern Denmark,Department of Clinical Research
[3] Odense University Hospital,Steno Diabetes Center Odense
[4] Vestfold Hospital Trust,Department of Ophthalmology
来源：
Ophthalmology and Therapy | 2023年 / 12卷
关键词：
Faricimab; Neovascular age-related macular degeneration; Diabetic macular oedema;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2253 / 2264
页数：11
相关论文
共 50 条
  • [1] Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
    Larsen, Helene O.
    Grauslund, Jakob
    Vergmann, Anna S.
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (05) : 2253 - 2264
  • [2] Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Desideri, Lorenzo Ferro
    Traverso, Carlo Enrico
    Nicolo, Massimo
    Munk, Marion R.
    PHARMACEUTICS, 2023, 15 (05)
  • [3] Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
    Toto, Lisa
    Formenti, Federico
    Ruggeri, Maria Ludovica
    Quarta, Alberto
    Romano, Anna
    De Nicola, Chiara
    Baroni, Luca Belloni
    Porreca, Annamaria
    Di Nicola, Marta
    Mastropasqua, Rodolfo
    OPHTHALMIC RESEARCH, 2024, 67 (01) : 528 - 536
  • [4] Faricimab for neovascular agerelated macular degeneration and diabetic macular oedema
    不详
    AUSTRALIAN PRESCRIBER, 2024, 47 (02) : 66 - 67
  • [5] Faricimab in neovascular age-related macular degeneration: updated week 48 efficacy, safety, and durability in the phase 3 TENAYA and LUCERNE trials
    London, Nikolas
    Guymer, Robyn H.
    Demetriades, Anna-Maria
    Ruiz, Carlos Quezada
    Silverman, David
    Ives, Jane
    Basu, Karen
    Lin, Hugh
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [6] Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials
    Khanani, Arshad
    Heier, Jeffrey
    Ruiz, Carlos
    Lin, Hugh
    Silverman, David
    Brittain, Christopher
    Ives, Jane
    Swaminathan, Balakumar
    Basu, Karen
    Wong, Tien
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [7] Efficacy of switching to brolucizumab for neovascular age-related macular degeneration refractory to faricimab
    Hoshino, Junki
    Matsumoto, Hidetaka
    Nakamura, Kosuke
    Akiyama, Hideo
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2025, : 221 - 229
  • [8] Faricimab Combination Therapy for Sustained Efficacy in Neovascular Age-Related Macular Degeneration
    De La Huerta, Irina
    Kim, Stephen J.
    Sternberg, Paul, Jr.
    JAMA OPHTHALMOLOGY, 2020, 138 (09) : 972 - 973
  • [9] Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema
    Diack, Cheikh
    Avery, Robert L.
    Cheung, Chui Ming Gemmy
    Csaky, Karl G.
    Gibiansky, Leonid
    Jaminion, Felix
    Gibiansky, Ekaterina
    Sickert, Denise
    Stoilov, Ivo
    Cosson, Valerie
    Bogman, Katrijn
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (11):
  • [10] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
12345